Interaction and signal transduction pathways of tum or necrosis factor-α and osteopontin in synovial fibroblasts of rheumatoid arthritis

Xu G, Nie H, Li N. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis [J]. Journal of Clinical Investigation, 2005(4):1060.

Petrow P K, Hummel K M, Schedel J. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis [J]. Arthritis and Rheumatism, 2000(7):1597.

Renkl A C, Wussler J, Ahrens T. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Thl-po-larizing phenotype [J]. Blood, 2005(3):946.

Shahrara S, Pickens S R, Dorfleutner A. IL-17 induces monocyte monocyte migratin in rheumatoid arthritis [J]. Journal of Immunology, 2009(6):3884.

Bradley K, Scatizzi J C, Fiore S. Retinoblastoma suppression of matrix metalloproteinase 1, but not interleukin-6, through ap38-dependent pathway in rheumatoid arthritis synovial fibroblasts [J]. Arthritis and Rheumatism, 2004(1):78.

Choe J Y, Lee S J, Park S H. Tacrolimus (FK506) inhibits interleukin-lβ-induced angiopoietin-1, Tie-2 receptor, and vascular endothelial growth factor through down-regulation of JNK and p38 pathway in human rheumatoid fibroblast-like synoviocytes [J]. Joint Bone Spine:Revue du Rhumatisme, 2012(2):137.

Kim H R, Park M K, Cho M L. Induction of macrophage migration inhibitory factor in ConA-stimulated rheumatoid arthritis synovial fibroblasts through the P38 map kinasedependent signaling pathway [J]. Korean Journal of Internal Medicine, 2010(3):317.

Panaro M A, Gagliardi N, Saponaro C. Toll-like receptor 4 mediates LPS-induced release of nitric oxide and tumor necrosis factor-alpha by embryonal cardiomyocytes:biological significance and clinical implications in human pathology [J]. Current Pharmaceutical Design, 2010(7):766.

Miwatashi S, Arikawa Y, Kotani E. Novel inhibitor of p38 MAP kinase as an anti-TNF-alph drug:discovery of N-[4=[2-ethyl4-(3-methylphenyl)-1, 3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent [J]. Journal of Medicinal Chemistry, 2005, (19):5966.